Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Apceth and Indivumed have collaborated to develop a predominantly tissue-based biomarker strategy for the treatment of solid cancers with cellular and / or gene therapeutics.
Subscribe to our email newsletter
The collaboration will analyse the response of a targeted therapy in different cancer types and stratify patients to provide a more individualized cancer treatment with Apceth’s cell and gene therapeutics.
A biomarker platform will enable oncologists to identify those patients who will most likely benefit from the treatment with Apceth’s therapeutics.
Apceth will leverage Indivumed’s highly regarded tumor tissue bank and its expertise in tissue-based biomarker discovery and validation.